Extracorporeal photopheresis (ECP) has been in clinical use for over three decades after
receiving FDA approval for the palliative treatment of the Sézary Syndrome variant of …

Extracorporeal photopheresis (ECP) is a leukapheresis-based therapy that uses 8-
methoxypsoralen and ultraviolet A irradiation. Used alone or in combination with biological …

Photopheresis or extracorporeal photochemotherapy (ECP) is a novel immunomodulatory
therapy which involves separation of the patient's leucocyte‐rich plasma, followed by ex vivo …

Background: Effective treatment modalities for systemic sclerosis, a life-threatening and
disabling disease, are still lacking. Possible efficacy of photopheresis has been reported in …

Extracorporeal photopheresis (ECP) is a well‐tolerated procedure that suppresses T‐
lymphocyte activity in a clonally‐specific way. It is an effective therapy that has established …

Background: Extracorporeal photochemotherapy (EP) is a new immune-modulating therapy
which combines cytapheresis and extracorporeal irradiation of leukocytes by UVA. Recently …

Background: The management of systemic sclerosis remains unsatisfactory. Thus far, the
action of extracorporeal photopheresis (ECP) in severe systemic scleroderma has been …

Photopheresis or extracorporeal photochemotherapy (ECP) is a novel immunomodulatory
therapy based upon pheresis of light‐sensitive cells. Whole blood is removed from patients …

Skeletal muscle abnormalities occur in some patients with scleroderma and manifestations
can vary from mild to severe. The incidence or prevalence of muscle involvement has been …

We are now aware that extracorporeal photopheresis (ECP)–in which a patient's leukocytes
are isolated, passed through an ultrathin clear plastic plate, and exposed to 8 …